Endocrine and immune effects of melatonin therapy in metastatic cancer patients

https://doi.org/10.1016/0277-5379(89)90122-3 Get rights and content

Abstract

Melatonin, the most important indole hormone produced by the pineal gland, appears to inhibit tumor growth; moreover, altered melatonin secretion has been reported in cancer patients. Despite these data, the possible use of melatonin in human neoplasms remains to be established. The aim of this clinical trial was to evaluate the therapeutic, immunological and endocrine effects of melatonin in patients with metastatic solid tumor, who did not respond to standard therapies. The study was carried out on 14 cancer patients (colon, six; lung, three; pancreas, two; liver, two; stomach, one). Melatonin was given intramuscularly at a daily dose of 20 mg at 3.00 p.m., followed by a maintenance period in an oral dose of 10 mg daily in patients who had a remission, stable disease or an improvement in PS. Before and after the first 2 months of therapy, GH, somatomedin-C, beta-endorphin, melatonin blood levels and lymphocyte subpopulations were evaluated. A partial response was achieved in one case with cancer of the pancreas, with a duration of 18+ months; moreover, six patients had stable disease, while the other eight progressed. An evident improvement in PS was obtained in 8 14 patients. In patients who did not progress, T 4 T 8 mean ratio was significantly higher after than before melatonin therapy, while it decreased in patients who progressed. On the contrary, hormonal levels were not affected by melatonin administration.

This study would suggest that melatonin may be of value in untreatable metastatic cancer patients, particularly in improving their PS and quality of life; moreover, based on its effects on the immune system, melatonin could be tested in association with other antitumor treatments.

References (30)

  • TK Das Gupta et al.

    Influence of pineal gland on the growth and spread of melanoma in hamsters

    Cancer Res

    (1967)
  • RM Barone et al.

    Role of pinealectomy in Walker 256 carcinoma in rats

    J Surg Oncol

    (1970)
  • AAH El-Domeiri et al.

    Reversal by melatonin of the effect of pinealectomy on tumor growth

    Cancer Res

    (1973)
  • C Aubert et al.

    Effect of pinealectomy and melatonin on mammary tumor growth in Sprague-Dawley rats under different conditions of lighting

    J Neural Transm

    (1980)
  • GJM Maestroni et al.

    Melatonin regulates immunity via an opiatergic mechanism

    Clin Neuropharmacol

    (1986)
  • Cited by (95)

    • Molecular basis of melatonin protective effects in metastasis: A novel target of melatonin

      2022, Biochimie
      Citation Excerpt :

      As reported by Lissoni et al. [63] administering MLT with IL-2 enhances the survival rate “due to a modulation of macrophage-mediated suppressive events which occur during IL-2 immunotherapy”. In two different studies, Lissoni and colleagues demonstrated that MLT increases the survival time in lung carcinoma patients with bone, soft tissue, and liver metastasis [63,64]. In 2019, an in vivo study also demonstrated the inhibitory effect of MLT on liver metastasis [42].

    • Melatonin as a multifunctional anti-cancer molecule: Implications in gastric cancer

      2017, Life Sciences
      Citation Excerpt :

      Moreover, disease control and tumor regression was achieved in some cases. These results prompted further evaluation of melatonin in cancer in the clinical setting [105]. In a subsequent study on patients suffering from metastatic non-small cell lung cancer (NSCLC) unresponsive to first-line chemotherapy, treatment with MT significantly increased 1-year survival and disease stabilization with an additional improvement of performance [106].

    • Physiological melatonin levels in healthy older people: A systematic review

      2016, Journal of Psychosomatic Research
      Citation Excerpt :

      In diverse conditions alterations in melatonin concentrations have been described. Bartsch, Lissoni and Mazzoccoli [5–10] investigated melatonin concentrations in breast, lung and prostate cancer patients and compared the levels in different stages of disease. They found a relationship between the stage of disease and the peak melatonin concentration, which decreased in advanced cancer, and appeared to be lower than in healthy persons.

    • Melatonin receptors in humans: Biological role and clinical relevance

      2006, Biomedicine and Pharmacotherapy
      Citation Excerpt :

      Furthermore, melatonin activates human monocytes by inducing cellular cytotoxic agents, such as interleukins and TNF-α [125]. In clinical trials carried out in metastatic cancer patients, melatonin and IL-1 were found to increase the CD4/CD8 ratio [126]. The mechanisms of melatonin action on the immune system include:

    View all citing articles on Scopus
    View full text